Amended Current Report Filing (8-k/a)
November 25 2019 - 5:16PM
Edgar (US Regulatory)
0000203527
false
0000203527
2019-08-16
2019-08-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported)
|
August 17, 2019
|
VARIAN MEDICAL SYSTEMS, INC.
|
(Exact Name of Registrant as Specified in its Charter)
|
Delaware
|
1-7598
|
94-2359345
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File
Number)
|
(IRS Employer
Identification No.)
|
3100 Hansen Way, Palo Alto, CA
|
94304-1030
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant's telephone number, including area code
|
(650) 493-4000
|
Not Applicable
|
(Former Name or Former Address, if Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:
|
Trading Symbol(s)
|
Name of each exchange on which registered:
|
Common Stock, $1 par value
|
VAR
|
New York Stock Exchange
|
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 17, 2019, Varian Medical
Systems, Inc. (the “Company”) filed a Current Report on Form 8-K announcing the election of Dr. Phillip Febbo as a
director of the Company effective August 17, 2019. The prior report did not include the committees of the Board of Directors that
Dr. Febbo was named to because the Board had not determined on which committees of the Board Dr. Febbo would serve. This Form 8-K/A
is being filed for the purpose of providing this information.
Effective November 23, 2019, Dr.
Febbo was appointed to the Audit Committee and the Ethics & Compliance Committee.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Varian Medical Systems, Inc.
|
|
|
|
By:
|
/s/ John W. Kuo
|
|
Name:
Title:
|
John W. Kuo
Senior Vice President, General Counsel and Corporate Secretary
|
Dated: November 25, 2019
Varian Medical System (NYSE:VAR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Varian Medical System (NYSE:VAR)
Historical Stock Chart
From Apr 2023 to Apr 2024